Sutro Biopharma Inc News - STRO | ADVFN

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Sutro Biopharma Inc (STRO)
Sutro Biopharma Inc (STRO) News

Sutro Biopharma Inc (STRO)

0.5246

-0.0154

(-2.85%)

Closed April 18 4:00PM

Delayed by 15 minutes

0.5395

0.0149

(2.84%)

After Hours: 7:59PM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable...

Form 4 - Statement of changes in beneficial ownership of securities

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg...

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

1
2
3
Next

FALCON1

FALCON1 1 week ago

Excellent time to seek "Defensive Stocks" due to economic headwinds caused by tariffs.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176042856

ELTP, an otc gem on the verge of M&A...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175821245

Invest-in-America

Invest-in-America 3 months ago

STRO: I launched this new iHub board today due to the below-pasted reply I got from GOOGLE's (AI) search routine regarding my following question: "Which (under $5.00) NASDAQ stock is the most likely to SOAR hugely in price on 1-2-25?"

"According to current market analysis, Sutro Biopharma Inc. (STRO), a clinical-stage biopharmaceutical company currently trading under $5, is considered a potential candidate for a significant price jump due to its promising cancer treatment pipeline, particularly its lead drug candidate "luveltamab tazevibulin" currently in mid-phase trials, which could lead to substantial investor interest if clinical trials prove successful; however, investing in any penny stock carries high risk and should be done with thorough research and consideration of potential downsides."

/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
And "TipRanks" gives STRO a "Strong Buy" rating, for what that's worth. (But its Float is 76-Million, which ain't small.)

Sutro Biopharma

TruSpine Technologies

Anfield Universal Fixed ...

Aptitude Software

ProShares Short FTSE Chi...

HSBC MSCI AC Far East Ex...

ProShares Short 20 plus ...

Russell Investments

Invesco California AMTFr...

CPI Aerostructures

Delayed Upgrade Clock